During the corresponding time, Dyadic International Inc saw a revenue deteriorated by -0.57 % year on year, sequentially revenue fell by -13.49 %. While revenue at the Dyadic International Inc 's corporate clients
Dyadic International Inc's Comment on Sales, Marketing and Customers
The company specializes in the commercialization of non-animal recombinant proteins using yeast platforms such as Pichia and Saccharomyces, as well as filamentous fungal platforms including Aspergillus and Trichoderma. Its competitive environment includes other companies, academic institutions, contract development and manufacturing organizations (CDMOs), and government-funded initiatives that may develop similar capabilities or alternative production technologies. The company's platforms are distinguished by scalability, productivity, cost efficiency, and glycan profiles. It operates under regulatory oversight from government authorities in the United States and other countries, including the U.S. Food and Drug Administration (FDA) for drug product approval and marketing.
Dyadic International Updates on Business Progress Amid Growing Focus on Alternative Proteins and Global Health Solutions JUPITER, Fla. September 23, 2024 Dyadic International, Inc. (NASDAQ: DYAI), a biotechnology company centered on the large-scale manufacture of proteins for various applications, has provided an update on its business endeavors while announcing its attendance at the Bioprocess International Conference in Boston from September 23-26, 2024. The company specializes in producing proteins for non-pharmaceutical uses, including food, nutrition, wellness, and animal and human health therapeutics and vaccines.In its recent update, Dyadic highlighted its ongoing commitment to developing innovati...
Dyadic International, Inc. (Dyadic), a renowned biotechnology company specializing in advanced microbial platforms, and the Israel Institute for Biological Research (IIBR) have recently announced the advancement of their collaboration to target emerging disease solutions. This partnership aims to combine Dyadic s expertise in microbial platforms for protein bioproduction with IIBR s antibodies and antigens discovery capabilities, to develop innovative solutions for addressing emerging diseases and potential bio-threats. The ultimate goal of this collaboration is to develop effective treatments and vaccines to combat global health challenges, with the intention of future commercialization through collaborativ...
Enhancing Quality Assurance in Biomanufacturing: Dyadic and Cygnus Technologies Partner to Provide C1 HCP ELISA AssayDyadic International Inc. (Dyadic) and Cygnus Technologies, part of Maravai LifeSciences, have recently joined forces in a strategic partnership to improve the quantification of Host Cell Proteins (HCP) in biomanufacturing processes. This collaboration aims to address the crucial need for enhanced quality assurance in the field by offering the C1 HCP ELISA Kit, developed by Cygnus, to Dyadic and Cygnus customers. The innovative technology involved in this partnership, along with its potential impact on the biomanufacturing industry, makes it a significant milestone in ensuring the safety and e...
Dyadic International Inc’s Comment on Sales, Marketing and Customers
The company specializes in the commercialization of non-animal recombinant proteins using yeast platforms such as Pichia and Saccharomyces, as well as filamentous fungal platforms including Aspergillus and Trichoderma. Its competitive environment includes other companies, academic institutions, contract development and manufacturing organizations (CDMOs), and government-funded initiatives that may develop similar capabilities or alternative production technologies. The company's platforms are distinguished by scalability, productivity, cost efficiency, and glycan profiles. It operates under regulatory oversight from government authorities in the United States and other countries, including the U.S. Food and Drug Administration (FDA) for drug product approval and marketing.
Sources:
Dyadic International Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Dyadic International Inc’s corporate clients.
For your research, we’ve provided 9 tables on Dyadic International Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
22.89 %